ArticleNature communications2022
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review.Human vaccines & immunotherapeutics · 2023Pooled it
- Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis.Lancet (London, England) · 2023Pooled it
- Intra-Omicron Reinfection with JN.1.16 and NB.1.8.1 in a Preterm Infant: First NB.1.8.1 Detection in Tunisia-A Case Report.Microorganisms · 2026Article
- Global Estimates of COVID-19 Morbidity and Mortality: A Cohort Study and Mathematical Model Analysis.Influenza and other respiratory viruses · 2025Article
- Effectiveness and durability of a fourth dose of ancestral-strain mRNA vaccines against SARS-CoV-2 infection: a nationwide matched cohort study in Qatar.Scientific reports · 2025Article
- Emergence of SARS-CoV-2 Omicron lineages shifted antibody-mediated protection curves.iScience · 2025Article
- Effectiveness of ChAdOx1 nCoV-19 (Vaxzevria) primary series vaccine against SARS-CoV-2 beta and delta variants: a nationwide study.BMC infectious diseases · 2025Article
- Modeling the Complete Dynamics of the SARS-CoV-2 Pandemic of Germany and Its Federal States Using Multiple Levels of Data.Viruses · 2025Article
- Protection conferred by SARS-CoV-2 infection across a spectrum of reinfection symptoms and severities.BMJ open respiratory research · 2025Article
- A data science pipeline applied to Australia's 2022 COVID-19 Omicron waves.Infectious Disease Modelling · 2025Article
- Article
- Planning and adjusting the COVID-19 booster vaccination campaign to reduce disease burden.Infectious Disease Modelling · 2025Article
- Article
- BNT162b2 Versus mRNA-1273 Vaccines: Comparative Analysis of Long-Term Protection Against SARS-CoV-2 Infection and Severe COVID-19 in Qatar.Influenza and other respiratory viruses · 2024Article
- A mini review of reinfection with the SARS-CoV-2 Omicron variant.Health science reports · 2024Article
- Extensive transmission of SARS-CoV-2 BQ.1* variant in a population with high levels of hybrid immunity: A prevalence survey.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024Article
- Addressing bias in the definition of SARS-CoV-2 reinfection: implications for underestimation.Frontiers in medicine · 2024Article
- Article
- COVID-19 vaccination strategies in settings with limited rollout capacity: a mathematical modelling case study in Sierra Leone.BMC public health · 2023Article
- Protective effect of previous infection and vaccination against reinfection with BA.5 Omicron subvariant: a nationwide population-based study in Japan.The Lancet regional health. Western Pacific · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is significant genetic distance between SARS-CoV-2 Omicron (B.1.1.529) variant BA.1 and BA.2 sub-lineages. This study investigates immune protection of infection with one sub-lineage against reinfection with the other sub-lineage in Qatar during a large BA.1 and BA.2 Omicron wave, from December 19, 2021 to March 21, 2022. Two national matched, retrospective cohort studies are conducted to estimate effectiveness of BA.1 infection against reinfection with BA.2 (N = 20,994; BA.1-against-BA.2 study), and effectiveness of BA.2 infection against reinfection with BA.1 (N = 110,315; BA.2-against-BA.1 study). Associations are estimated using Cox proportional-hazards regression models after multiple imputation to assign a sub-lineage status for cases with no sub-lineage status (using probabilities based on the test date). Effectiveness of BA.1 infection against reinfection with BA.2 is estimated at 94.2% (95% CI: 89.2-96.9%). Effectiveness of BA.2 infection against reinfection with BA.1 is estimated at 80.9% (95% CI: 73.1-86.4%). Infection with the BA.1 sub-lineage appears to induce strong, but not full immune protection against reinfection with the BA.2 sub-lineage, and vice versa, for at least several weeks after the initial infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.